Lataa...
(32)P in the treatment of myeloproliferative disorders
(32)P has been available for the treatment of myeloproliferative neoplasms (MPNs) for over seventy years. It was first used in 1938 by John H Lawrence in the treatment of polycythaemia and chronic leukaemias. With the introduction of agents such as hydroxycarbamide, interferon and anagrelide the rol...
Tallennettuna:
| Julkaisussa: | Ulster Med J |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
The Ulster Medical Society
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4920483/ https://ncbi.nlm.nih.gov/pubmed/27601760 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|